Pharmaceutical Pellet Coating for pH-Independent Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current controlled-release pharmaceutical dosage forms face challenges in achieving consistent release profiles due to pH variability in the gastrointestinal tract and enzyme interactions, leading to inconsistent drug absorption and duration of action, and difficulties in producing uniformly coated pellets with smooth surfaces.
Innovation Solution
Development of pharmaceutical pellets with a spherical core containing the active substance and a smooth surface, coated with a pH-independent release-controlling coating composed of polyvinyl acetate, triethyl citrate, and talc, which allows for controlled release profiles independent of pH and enzyme action, including a lag-phase followed by a defined release rate.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If pellets are produced by extrusion, then production efficiency is improved, but surface smoothness and shape uniformity deteriorate
Solution Approach 1:
The production process is divided into two distinct stages: first producing pellets by extrusion (prioritizing productivity), then separately smoothing the surfaces through tumbling with polishing media (prioritizing surface quality). This segmentation allows each stage to optimize for its specific function without compromising the other.
Solution Approach 2:
The extrusion process produces pellets with adequate but not optimal surface finish. The preliminary action of extrusion creates the basic pellet structure efficiently, followed by a subsequent smoothing action that refines the surface. This preliminary action approach allows high-speed production while achieving required surface smoothness through a dedicated follow-up step.
2Reliability
If coatings are applied to control active substance release, then release control is improved, but coating uniformity deteriorates due to rough pellet surfaces
Solution Approach 1:
The pellet surface is smoothed through tumbling with polishing media before the coating application step. This preliminary surface preparation ensures that when coating is subsequently applied, it adheres uniformly to a consistent surface, eliminating the problem of rough surfaces causing non-uniform coating thickness and distribution.
3Device complexity
If pH-controlled release systems are used, then release control mechanism is simplified, but release consistency deteriorates due to pH variability in gastrointestinal tract
Solution Approach 1:
The coating formulation is specifically designed with polymers and plasticizers that maintain their membrane properties across the wide pH range found in the gastrointestinal tract (pH 1-8). By changing the material parameters to be pH-insensitive, the system achieves reliable release control that is independent of the variable pH environment, while still maintaining a relatively simple membrane-based release mechanism.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solution enables consistent and controlled release of the active substance, independent of pH and enzyme activity, with a lag-phase and subsequent rapid release, ensuring predictable drug absorption and duration of action, while maintaining a high percentage of active substance release within a specified timeframe.
Implementation Method 1
the release of the active substance takes place independently of pH and independently of enzymes, if pellets are used that have a spherical core containing the active substance with a smooth surface and a coating on the core
Implementation Method 2
coating on the core
Data Source
AI summary
A pharmaceutical pellet is disclosed, comprising a spherical core containing active ingredient with a smooth surface and a coating on the core which controls the release of the active ingredient in a pH-independent manner. With such a pellet the release of the active ingredient can follow a profile with a lag phase of 60 minutes to 840 minutes, a proportion of 5 wt. % or less of the active ingredient being released during the lag phase. The active ingredient can furthermore be released from the pellet with a profile such that after the lag phase the release of the active ingredient amounts to between 3 and 25 wt. % per hour.